|Videos|December 30, 2022

2022 recap: Dr. Chi highlights milestones in stone disease

Author(s)Urology Times staff

“We've got a lot of movement in terms of understanding how stones form, some pharmaceutical interventions that we can use to prevent stones, and then how we can get even less invasive to try to get stones in the least morbid way for our patients,” says Thomas Chi, MD.

Urology Times^® is wrapping up the year by diving into some milestones from different urologic specialties. In this interview, Thomas Chi, MD, recaps some of the clinical and research highlights in stone disease from the past year. Chi is a professor and associate chair at the University of California, San Francisco.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Residual stone volume outperforms stone-free rate as risk marker

ByBrett Johnson, MD

July 17th 2026

Amy E. Krambeck, MD, on choosing between CVAC and FANS for suction-based ureteroscopy

ByAmy E. Krambeck, MD

July 10th 2026

Study links unmet social needs with worse stone-specific quality of life

ByMichael John Mari Talagsa Uy, MD

July 6th 2026

From OR to office: How Break Wave changes urology practice workflow

ByBen H. Chew, MD, MSc

July 3rd 2026

Economic analysis: SURE reduces downstream stone costs

ByBrett Johnson, MD

July 1st 2026

Latest CME

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom

Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery

Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy

Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care